Clinical Trials

Lymphoma, Follicular, Recurrence

NCT04094311 2026-02-17

Study of Out of Specification for Tisagenlecleucel

Phase 3 Recruiting

200 enrolled

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05075603 2025-10-23

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Phase 1 Completed

17 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03568461 2025-10-07

ELARA

98 enrolled 9 charts 1 FDA

Lymphoma, Follicular, Recurrence

NCT03610724 2024-06-20

BIANCA

34 enrolled 19 charts

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02445248 2024-04-18

JULIET

115 enrolled 22 charts 1 FDA

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02435849 2024-02-13

ELIANA

80 enrolled 39 charts 1 FDA

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04156659 2023-03-09

Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL

Phase 2 Withdrawn

Burkitt Lymphoma

NCT03876028 2023-01-31

Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

Phase 1 Terminated

10 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03630159 2022-08-15

PORTIA

Phase 1 Completed

12 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04456023 2022-03-02

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Phase 2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03123939 2021-07-21

Phase III B in Acute Lymphoblastic Leukemia

Phase 3 Completed

69 enrolled 26 charts

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02228096 2020-11-23

ENSIGN

75 enrolled 41 charts

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03628053 2020-07-09

OBERON

Phase 3 Withdrawn